Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis

Meikle, Claire K.; Meisler, Adam; Bird, Cara M.; Jeffries, Joseph A.; Azeem, Nabila; Garg, Priyanka; Crawford, Erin L.; Kelly, Clare A.; Gao, Tess; Wuescher, Leah M.; Willey, James C.; Worth, Randall G.

doi:10.1371/journal.pone.0236966

Cited by 22 publications

(17 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although Gas6 regulates inflammatory functions in immune and endothelial cells, in lung cancer cell-associated venous thrombosis model, Gas6 enhanced prostaglandin E2 (PGE2) secretion from the endothelium leading to platelet activation and venous thrombosis ( 37 ). The interactions of platelets with T cells also contribute to an inflammatory pro-coagulant phenotype and thrombosis in patients with lung cancer ( 38 ).…”

Section: Cancer-associated Thrombosis and Thrombo-inflammationmentioning

confidence: 99%

Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues

et al. 2021

View full text Add to dashboard Cite

Although platelets are critically involved in thrombosis and hemostasis, experimental and clinical evidence indicate that platelets promote tumor progression and metastasis through a wide range of physical and functional interactions between platelets and cancer cells. Thrombotic and thromboembolic events are frequent complications in patients with solid tumors. Hence, cancer modulates platelet function by directly inducing platelet-tumor aggregates and triggering platelet granule release and altering platelet turnover. Also, platelets enhance tumor cell dissemination by activating endothelial cell function and recruiting immune cells to primary and metastatic tumor sites. In this review, we summarize current knowledge on the complex interactions between platelets and tumor cells and the host microenvironment. We also critically discuss the potential of anti-platelet agents for cancer prevention and treatment.

show abstract

Section: Cancer-associated Thrombosis and Thrombo-inflammationmentioning

confidence: 99%

Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Lung cancer is a common malignant tumor that has the characteristics of high incidence, high mortality, and many complications, which seriously endangers human health and safety. Thrombosis is one of the common complications of lung cancer, and hypercoagulable state is the direct factor of thrombosis [ 1 , 2 ]. Hypercoagulable state, also known as prethrombotic state, is a pathological state with dysfunction caused by injury of vascular endothelial cells, such as abnormal clotting and fibrinolysis.…”

Section: Introductionmentioning

confidence: 99%

Relationship between Hypercoagulable State and Circulating Tumor Cells in Peripheral Blood, Pathological Characteristics, and Prognosis of Lung Cancer Patients

Jiao

Guo

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To analyze the relationship between hypercoagulable state and circulating tumor cells (CTCs) in peripheral blood, pathological characteristics, and prognosis of lung cancer patients. Method. A total of 148 patients with primary lung cancer diagnosed and treated in our hospital from January 2017 to January 2019 were selected as the research objects. According to the CTC test results, the patients were divided into CTC-positive group and CTC-negative group. Also, the coagulation index of patients was tested. According to the blood coagulation index test results, patients were divided into hypercoagulable group and non-hypercoagulable group. The relationship between hypercoagulable state and pathological characteristics of lung cancer patients was analyzed by single factor analysis and multiple logistic regression model. Kaplan–Meier survival curve was applied to analyze the relationship between hypercoagulable state and the prognosis of lung cancer patients. Results. The platelets (PLTs), fibrinogen (FIB), D-dimer (D-D), and prothrombin time (PT) in CTC-positive group were significantly higher than those in CTC-negative group. There was no significant relationship between the patient’s gender, smoking history, pathological type, and the hypercoagulable state of the patients. The proportion of patients aged 60 years or older, with TMN stage III or IV and lymph node metastasis, in the hypercoagulable group was significantly higher than that in the non-hypercoagulable group. Logistic regression analysis showed that there was an independent relationship between the patient’s age, lymph node metastasis, and hypercoagulable state. As of January 2020, among the 148 patients with lung cancer follow-up, 5 patients were lost and 52 died. The median survival time of patients in the hypercoagulable group was 82 weeks, which was significantly lower than the 104 weeks in the nonhypercoagulable group. Conclusion. There is a certain relationship between hypercoagulable state and CTC positive in lung cancer patients. There is an independent relationship between the patient’s age, lymph node metastasis, and the hypercoagulable state. The median survival time of patients in the hypercoagulable group was significantly lower than that in the non-hypercoagulable group.

show abstract

“…prostaglandin E2, PGE2) эндотелием, что приводит к активации тромбоцитов и венозному тромбозу [22]. Взаимодействие тромбоцитов с Т-клетками также усиливает провоспалительно-прокоагулянтное состояние и способствует развитию тромбоза у пациентов с раком легкого [23] (рис. 2).…”

Section: активация тромбоцитов индуцированная опухолевыми клетками / Tumor Cell-induced Platelet Activationunclassified

Platelets, thrombo-inflammation and cancer

Slukhanchuk

Bitsadze

Khizroeva

et al. 2021

Akušerstvo, ginekologiâ i reprodukciâ

View full text Add to dashboard Cite

It has long been recognized a crucial role played by platelets in thrombosis and hemostasis. Along with that, laboratory and clinical data suggest that platelets contribute to tumor progression and metastasis through a variety of interactions with cancer cells. During oncological process, the platelet function becomes modulated via their activation and increased aggregation being one of the risk factors for developing thrombosis in cancer patients. The platelets per se enhance tumor cell dissemination, activate endothelial cells, and attract immune cells to the primary and metastatic tumor sites. In this review, we summarize the current knowledge about the complex interactions between platelets and tumor cells, as well as cells of the microenvironment, and discuss the development of new antitumor agents aimed at various arms in platelet functioning.

show abstract

Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis

Cited by 22 publications

References 53 publications

Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues

Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues

Relationship between Hypercoagulable State and Circulating Tumor Cells in Peripheral Blood, Pathological Characteristics, and Prognosis of Lung Cancer Patients

Platelets, thrombo-inflammation and cancer

Contact Info

Product

Resources

About